Bin Tang

Title: The Innovations of Bin Tang

Introduction

Bin Tang is a notable inventor based in Changchun, China. He has made significant contributions to the field of medical diagnostics, particularly in the prevention and treatment of infectious diseases. His work focuses on developing innovative solutions to address specific technical problems in the medical field.

Latest Patents

Bin Tang holds a patent for a hybridoma cell strain and a monoclonal antibody produced against serine protease of intestinal stage. This invention aims to provide a specific diagnostic method for trichinellosis. The patent describes a hybridoma cell strain deposited under the accession number CGMCC No. 18317. The monoclonal antibody, Ts-ZH68-2A4-Ab, secreted by this hybridoma cell strain, has shown the ability to compete with positive serum from infected pigs for binding to the Ts-ZH68 antigen. The recognition peptide associated with this antibody is GVDRSATCQGDSGGP. This innovation lays the groundwork for developing a reagent or vaccine for diagnosing or preventing infections, thus establishing a serological diagnosis method.

Career Highlights

Bin Tang is affiliated with Jilin University, where he continues to advance his research and innovations. His work has garnered attention for its potential impact on public health and disease prevention.

Collaborations

He has collaborated with colleagues such as Mingyuan Liu and Xiaolei Liu, contributing to the advancement of research in his field.

Conclusion

Bin Tang's innovative work in developing a hybridoma cell strain and monoclonal antibody represents a significant advancement in the diagnosis and prevention of trichinellosis. His contributions to medical science highlight the importance of innovation in addressing public health challenges.